AI assistant
Diasorin Proxy Solicitation & Information Statement 2022
4129_def-14a_2022-04-13_3b56ad1b-379c-4aa2-83fd-f012b407a799.pdf
Proxy Solicitation & Information Statement
Open in viewerOpens in your device viewer
| Informazione Regolamentata n. 0957-20-2022 |
Data/Ora Ricezione 13 Aprile 2022 16:41:55 |
Euronext Milan | |
|---|---|---|---|
| Societa' | : | DiaSorin | |
| Identificativo Informazione Regolamentata |
: | 160391 | |
| Nome utilizzatore | : | DIASORINN01 - Ulisse Spada - Valerio Vaccarone |
|
| Tipologia | : | 3.1 | |
| Data/Ora Ricezione | : | 13 Aprile 2022 16:41:55 | |
| Data/Ora Inizio Diffusione presunta |
: | 13 Aprile 2022 16:41:56 | |
| Oggetto | : | Publication of the updated proxy forms for voting through the Designated Representative |
|
| Testo del comunicato |
Please see the attachment.
DIASORIN: PUBLICATION OF THE UPDATED PROXY FORMS FOR VOTING THROUGH THE DESIGNATED REPRESENTATIVE
Saluggia, April 13, 2022 – With reference to the Shareholders' meeting called on April 29 2022 in a single calling, DiaSorin (FTSE MIB: DIA) announces that the proxy forms for voting through the Designated Respresentative, updated in the light of the proposals for resolution filed by the shareholder IP Investimenti e Partecipazioni S.r.l., are available to the public on the Company's website (www.diasoringroup.com, section "Governance"/ "Shareholders meetings"/"2022") and on the authorized storage mechanism used by the Company available on the website .
For additional information, please contact:
Riccardo Fava Emanuela Salvini Corporate Vice President Communication & Investor Relations Investor Relator Tel: +39.0161.487988 Tel: +39.0161.487567 [email protected] [email protected]
About DiaSorin
Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.
The Group operates in 5 continents through 43 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".
More info at www.diasoringroup.com
